Drugs / TVAX-028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07673068 | May 2026 → May 2027 expected | chronic hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TVAX-028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07673068 ↗ |